Eagle Capital Management (New York)
TEVA icon

Eagle Capital Management (New York)’s Teva Pharmaceuticals TEVA Stock Holding History

Eagle Capital Management (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-22,400
Closed -$846K – 59
2013
Q3 		$846K Hold
22,400
– – ﹤0.01% 40
2013
Q2 		$878K Buy
+22,400
New +$872K ﹤0.01% 38

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eagle Capital Management (New York)'s TEVA Position: Q4 2013 in Review

Eagle Capital Management (New York) sold out of Teva Pharmaceuticals (TEVA) in Q4 2013, closing a stake of 22,400 shares — an estimated $846K sold.

Eagle Capital Management (New York) first reported a position in TEVA in Q2 2013 and held it in 2 quarters. The position peaked at $878K in Q2 2013. 727 funds tracked by Wall St. Rank hold TEVA as of Q4 2013.

  • Eagle Capital Management (New York) reported no remaining Teva Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Eagle Capital Management (New York) sold 22,400 Teva Pharmaceuticals shares in Q4 2013, an estimated $846K.
  • Eagle Capital Management (New York) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Eagle Capital Management (New York)'s Teva Pharmaceuticals position peaked at $878K in Q2 2013.
  • 727 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2013.

Based on Eagle Capital Management (New York)'s 13F filing for Q4 2013, filed 14 Feb 2014.